NASDAQ: PSTV - Plus Therapeutics, Inc.

Yield per half year: -53.83%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Plus Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Plus Therapeutics, Inc.

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186Re obisbemeda, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.

more details
The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2000-11-16
ISIN US72941H4002
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://plustherapeutics.com
Цена ао 1.47
Change price per day: +0.1538% (0.65)
Change price per week: -22.5% (0.84)
Change price per month: +10.34% (0.59)
Change price per 3 month: -45.78% (1.2007)
Change price per half year: -53.83% (1.41)
Change price per year: -63.12% (1.765)
Change price per 3 year: -32.89% (0.97)
Change price per 5 year: -38% (1.05)
Change price per year to date: -43.39% (1.15)
All parameters

Underestimation

Title Value Grade
P/S 1.22 9
P/BV -4.45 0
P/E 0 0
EV/EBITDA -0.1293 0
Total: 4.88

Efficiency

Title Value Grade
ROA, % -116.93 0
ROE, % 987.83 10
Total: 3.33

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.3325 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 63.77 8
Yield Ebitda, % 370.11 10
Yield EPS, % -96.93 0
Total: 5.8
More

Institutions Volume Share, %
Renaissance Technologies, LLC 33000 0.77
Vanguard Group Inc 32541 0.76
Geode Capital Management, LLC 26543 0.62
Citadel Advisors Llc 16839 0.39
Ground Swell Capital, LLC 14303 0.33
UBS Group AG 8899 0.21
Blackrock Inc. 6960 0.16
Tower Research Capital LLC (TRC) 572 0.01
Osaic Holdings Inc 133 0
JP Morgan Chase & Company 99 0



Head Job title Payment Year of birth
Dr. Marc H. Hedrick M.B.A., M.D. President, CEO & Director 945.34k 1963 (62 years)
Mr. Andrew J. Sims CPA VP of Finance & CFO 498.51k 1973 (52 years)
Ms. Desiree Smith Corporate Controller, Principal Financial & Accounting Officer N/A 1964 (61 year)
Dr. John K. Fraser Chief Scientist N/A 1961 (64 years)

Address: United States, Austin. TX, 4200 Marathon Boulevard - open in Google maps, open in Yandex maps
Website: https://plustherapeutics.com